본문 바로가기
KERD
논문KCI 등재

Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy

0

조회

0

다운로드

0

인용

0

참고문헌

키워드

주제분류의학일반

초록

Purpose Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a rare subtype of non- Hodgkin lymphoma, and asparaginase-based regimens are the best first-line treatments. Data on the role of specific circulating lymphocyte subsets in the progression of ENKTL are limited. The aim of this study was to investigate the clinical correlation and distribution of circulating absolute CD4+ T-cell counts (ACD4Cs) in ENKTL. Materials and Methods We retrospectively searched medical records for 70 newly diagnosed ENKTL patients treated with pegaspargase-based regimens. Comparison of ACD4Cs as a continuous parameter in different groups was calculated. Univariate and multivariate analyses were used to assess prognostic factors for overall survival (OS) and progression-free survival (PFS). Results Stage III/IV, B symptoms, elevated lactate dehydrogenase, monocytopenia, high-intermediate and high risk International Prognostic Index (IPI) and Korean Prognostic Index (KPI), high risk Prognostic Index of Natural Killer Lymphoma (PINK), and lower lymphocytes were significantly associated with low ACD4C at diagnosis. With a median follow-up time of 32 months, patients who had an ACD4C < 0.30109/L had a worse OS. Median OS was 11 months and median PFS was 5 months in the low ACD4C cohort. There were significant differences in both OS and PFS between the two cohorts. Moreover, multivariate Cox analysis identified ACD4Cs as an independent predictor for OS and PFS. Conclusion Low ACD4Cs were associated with poorer survival and could act as a negative predictor for ENKTL patients treated with asparaginase-based regimens.

Abstract

Purpose Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a rare subtype of non- Hodgkin lymphoma, and asparaginase-based regimens are the best first-line treatments. Data on the role of specific circulating lymphocyte subsets in the progression of ENKTL are limited. The aim of this study was to investigate the clinical correlation and distribution of circulating absolute CD4+ T-cell counts (ACD4Cs) in ENKTL. Materials and Methods We retrospectively searched medical records for 70 newly diagnosed ENKTL patients treated with pegaspargase-based regimens. Comparison of ACD4Cs as a continuous parameter in different groups was calculated. Univariate and multivariate analyses were used to assess prognostic factors for overall survival (OS) and progression-free survival (PFS). Results Stage III/IV, B symptoms, elevated lactate dehydrogenase, monocytopenia, high-intermediate and high risk International Prognostic Index (IPI) and Korean Prognostic Index (KPI), high risk Prognostic Index of Natural Killer Lymphoma (PINK), and lower lymphocytes were significantly associated with low ACD4C at diagnosis. With a median follow-up time of 32 months, patients who had an ACD4C < 0.30109/L had a worse OS. Median OS was 11 months and median PFS was 5 months in the low ACD4C cohort. There were significant differences in both OS and PFS between the two cohorts. Moreover, multivariate Cox analysis identified ACD4Cs as an independent predictor for OS and PFS. Conclusion Low ACD4Cs were associated with poorer survival and could act as a negative predictor for ENKTL patients treated with asparaginase-based regimens.

참고문헌 (27)

  1. Yang QP, "Subtype distribution of lymphomas in Southwest China : analysis of 6, 382 cases using WHO classification in a single institution", Diagn Pathol, 6, pp.77~ (2011)
  2. Xu W, "Distribution of lymphomas subtypes in Jiangsu Province : a multicenter analysis of 5 147 cases", Zhonghua Xue Ye Xue Za Zhi, 35, pp.300~303 (2014)
  3. Au WY, "Clinical differences between nasal and extranasal natural killer", T-cell lymphoma : a study of 136cases from the International Peripheral T-Cell Lymphoma Project, 2009, pp.113, 3931~3937
  4. Perry AM, "Non-Hodgkin lymphoma in the Far East : review of 730 cases from the international non-Hodgkin lymphoma classification project", Ann Hematol, 95, pp.245~251 (2016)
  5. Lee J, "Extranodal natural killer T-cell lymphoma, nasal-type : a prognostic model from a retrospective multicenter study", J Clin Oncol, 24, pp.612~618 (2006)
  6. Kim SJ, "A prognostic index for natural killer cell lymphoma after nonanthracycline-based treatment : a multicentre, retrospective analysis", Lancet Oncol, 17, pp.389~400 (2016)
  7. Peng RJ, "Circulating and tumor-infiltrating Foxp3(+)regulatory T cell subset in Chinese patients with extranodal NK", T cell lymphoma, 2011, pp.7, 1027~1036
  8. Kwong YL, "PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK", T-cell lymphoma failing l-asparaginase, 2017, pp.129, 2437~2442
  9. Huang JJ, "Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer", T-cell lymphoma, nasal type, 2011, pp.22, 149~155
  10. Wang L, "Lymphopenia during routine follow-up may predict relapse in patients with extranodal NK", T cell lymphoma, 2015, pp.36, 1747~1753
  11. Yang Y, "Prognostic nomogram for overall survival in previously untreated patients with extranodal NK", T-cell lymphoma, nasal-type : a multicenter study, 2015, pp.29, 1571~1577
  12. Suzuki R, "Prognostic factors for mature natural killer(NK)cell neoplasms : aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type", Ann Oncol, 21, pp.1032~1040 (2010)
  13. He L, "Low absolute CD4(+)T cell counts in peripheral blood are associated with inferior survival in follicular lymphoma", Tumour Biol, 37, pp.12589~12595 (2016)
  14. Zhang XY, "Negative prognostic impact of low absolute CD4(+)T cell counts in peripheral blood in mantle cell lymphoma", Cancer Sci, 107, pp.1471~1476 (2016)
  15. Sabattini E, "WHO classification of tumours of haematopoietic and lymphoid tissues in 2008 : an overview", Pathologica, 102, pp.83~87 (2010)
  16. Camp RL, "X-tile : a new bioinformatics tool for biomarker assessment and outcome-based cut-point optimization", Clin Cancer Res, 10, pp.7252~7259 (2004)
  17. Gaulard P, "The microenvironment in T-cell lymphomas : emerging themes", Semin Cancer Biol, 24, pp.49~60 (2014)
  18. Coupland SE, "The challenge of the microenvironment in B-cell lymphomas", Histopathology, 58, pp.69~80 (2011)
  19. Blaker YN, "The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era", Br J Haematol, 175, pp.102~114 (2016)
  20. Wein F, "The role of T cells in the microenvironment of Hodgkin lymphoma", J Leukoc Biol, 99, pp.45~50 (2016)
  21. Chang C, "High levels of regulatory T cells in blood are a poor prognostic factor in patients with diffuse large B-cell lymphoma", Am J Clin Pathol, 144, pp.935~944 (2015)
  22. Chim CS, "Primary nasal natural killer cell lymphoma : long-term treatment outcome and relationship with the International Prognostic Index", Blood, 103, pp.216~221 (2004)
  23. Kim WY, "Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK", T-cell lymphoma, 2009, pp.20, 1688~1696
  24. Salama P, "Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer", J Clin Oncol, 27, pp.186~192 (2009)
  25. Hsieh PP, "EBV viral load in tumor tissue is an important prognostic indicator for nasal NK", T-cell lymphoma, 2007, pp.128, 579~584
  26. Ding ZC, "Polyfunctional CD4(+)T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy", Blood, 120, pp.2229~2239 (2012)
  27. Bos R, "CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes", Cancer Res, 70, pp.8368~8377 (2010)

관련 논문AI추천

Characteristics, Prognostic Factors, and Survival of Patients with NK/T-Cell Lymphoma of Non-upper Aerodigestive Tract: A 17-Year Single-Center ExperienceDe-Xin Lei, Hang Yang, Pan-Pan Liu, Wen-Qi Jiang, Xi-Wen Bi, Xue-Wen Zhang, Yan Gao, Yi Xia, Yuan-Xue Jiang, Ze-Long Liu대한암학회 · Cancer Research and Treatment2019 · 제51권 제4호A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK김신, 강소라, 강은희, 고영혜, 고현정, 김석진, 김원석, 류진숙, 박정선, 박찬식, 서철원, 윤상은, 이경민, 이상욱, 이윤세, 조형우, 허주령대한암학회 · Cancer Research and Treatment2023 · 제55권 제1호Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type김동완, 김미소, 김범석, 김일한, 김태민, 김현지, 옥찬영, 이성희, 이주연, 정선회, 조윤숙, 허대석대한암학회 · Cancer Research and Treatment2018 · 제50권 제3호Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study김수정, 김유리, 김진석, 민유홍, 이혜선, 장지은, 전소영, 정준원, 정혜림, 조현수대한암학회 · Cancer Research and Treatment2022 · 제54권 제2호Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea강혜진, 고영일, 권지현, 김석진, 도영록, 윤상은, 이원식, 이정옥, 이준호, 이지윤, 이지현, 임성남, 조재철, 조형우, 허준영대한암학회 · Cancer Research and Treatment2024 · 제56권 제2호Clinical Impact of Microbiome Characteristics in Treatment-Naïve Extranodal NK/T-Cell Lymphoma Patients김현, 강우림, 김석진, 김원석, 윤상은, 이제희, 조준훈, 현동욱, Chalita Mauricio대한암학회 · Cancer Research and Treatment2025 · 제57권 제2호

이 간행물의 다른 논문 (39건)

S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial김봉석, 장대영, 라선영, 김기향, 강석윤, 이문희, 정현철, 정민규, 형우진, 이충근, 김효송, 정재호, 신동복, 정인경, 이경희, 노성훈pp. 1-11The Effect of Hospital Case Volume on Clinical Outcomes in Patients with Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Analysis (KROG-1106)김진호, 노재명, 이종훈, 김성환, 최진화, 김연실, 김원택, 오영택, 강민규, 김진희, 조관호, 이창걸, 김지윤, 문성호, 조문준, 안용찬, 금기창, 우홍균, 오동률, 하보람, 계철승pp. 12-23Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma김명진, 최진영, 박미숙, 이진용, 한경화, 강창무, 정용은, 김혜진pp. 24-33The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy EraSi-Yang Wang, Dong-Mei Mai, Yu-Yun Du, Dong-Hua Luo, Hao-Yuan Mo, Wang-Jian Zhang, Wayne R. Lawrence, Ya-Nan Jin, Xiu-Yu Cai, Mei-Su Lipp. 34-42Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)손주혁, 정경해, 박연희, 이경훈, 김태용, 박인혜, 이수이, 임석아, 노정실, 박경화, 김지현, 심성훈, 이근석, 안진희, 김성배, 남병호, 김희준pp. 43-52